# Biodesix

Biodesix is an other based in Louisville, United States.

## Overview

- **Organization type:** other
- **Headquarters:** Louisville, United States
- **Region:** North America
- **Address:** Louisville, CO, United States
- **Assets under management:** Undisclosed
- **Website:** biodesix.com
- **LinkedIn:** https://www.linkedin.com/company/biodesix-inc-

## Regulatory record

- **Reports private funds:** No

## About

Our mission is to transform patient care and improve outcomes through personalized diagnostics that are timely, accessible, and address immediate clinical needs.

## Sectors

- Digital Health
- Healthcare Services

## Offices

- De Soto, KS, United States

## Questions

### What tests does Biodesix offer for lung nodule evaluation?

Biodesix offers Nodify XL2 and Nodify CDT for lung nodule risk assessment. Nodify XL2 integrates clinical factors with two plasma proteins to rule out malignancy with high negative predictive value, while Nodify CDT evaluates a broader panel of circulating protein markers to assess risk. Both are performed in the company's own CLIA-certified laboratory in Louisville, Colorado.

### How does Biodesix make money?

Revenue splits across two segments: clinical diagnostic services sold to physicians and hospitals, and biopharmaceutical development services where Biodesix runs companion diagnostic testing and validation for drug developers. The clinical business bills payers and institutions for each test performed; the biopharma business generates service fees and milestone-based payments tied to clinical trials.

### Is Biodesix a public company?

Yes. Biodesix completed a business combination with a special purpose acquisition company in 2021 and now trades on the Nasdaq under the ticker BDSX. This provides public financial disclosures and SEC filings that investors can review for commercial performance.

### What cancers does Biodesix's testing address?

The company's menu focuses specifically on lung disease — including pulmonary nodule evaluation and treatment selection for non-small cell lung cancer. Tests like VeriStrat provide proteomic profiling to guide therapy choices, while GeneStrat offers genomic tumor profiling from a blood draw. The platform does not currently extend to other solid-tumor or hematologic cancers.

## Related profiles

- [Health Wildcatters](https://altss.com/profile/health-wildcatters)
- [Dean Foods](https://altss.com/profile/dean-foods-company)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/biodesix

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology